companiesCompany
Everest Medicines
aka Everest Medicines Limited, 云顶新耀, HKEX:1952
Everest Medicines is a Shanghai company that brings in medicines for Asia and is building an mRNA platform, including the personalised cancer vaccine EVM16 and the off-the-shelf tumour vaccine EVM14.
Overview
Everest Medicines, listed in Hong Kong, licenses and commercialises medicines in Greater China and other Asian markets, including Nefecon for IgA nephropathy and the antibiotic Xerava. It has built its own mRNA platform and manufacturing site in Jiaxing; EVM14 is an mRNA cancer vaccine encoding shared tumour-associated antigens for squamous cancers of the lung and head and neck, and EVM16 is a personalised neoantigen vaccine. Both entered clinical testing in 2025.
Headquarters
Shanghai, CN
Scorecard
All companies#437of 1181 companies, score 5
- phase 1/2 +1
- modalities +2
- registry trials +2
0 approved, 0 in phase 3, 1 earlier, 0 targets, 1 registry studies. Formula on the scorecards page.
Type
pharma · HKEX:1952
Stage
Public
Website
Founded
2017